Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

Autors de IIS La Fe

• Joaquin Berenguer Lapuerta

  Autor

• Fernando Lozano

  Autor

• José López Aldeguer

  Autor

• Vicenta Asensi Gimeno

  Autor

• Pere Domingo Pedrol

  Autor

• María Jose Galindo Puerto

  Autor

• 

  Antonio Pineda Lucena

  Autor

• Tatiana Fernandez Portilla

  Autor

• Esteban Ribera Pascuet

  Autor

Autors aliens a IIS La Fe

• Expert Panel of GeSIDA and the National Aids Plan
• Polo R
• Antela A
• Arribas JR
• Blanco JR
• Clotet B
• Gatell JM
• González-García J
• Iribarren JA
• Locutura J
• López JC
• Mallolas J
• Martínez E
• Miralles C
• Miró JM
• Moreno S
• Palacios R
• Pérez Elías MJ
• Podzamczer D
• Pulido F
• Riera M
• Rubio R
• Santos J
• Sanz J
• Tuset M
• Vidal F
• Rivero A

Grups d'Investigació

• Investigacion clínica en enfermedades crónicas e Infección por el VIH

  Investigador establecido

  Marta Montero Alonso

Abstract

In this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation varies with clinical circumstances, number of CD4 cells, comorbid conditions and prevention of transmission of HIV. The objective of ART is to achieve an undetectable plasma viral load. Initial ART should always comprise a combination of 3 drugs, including 2 nucleoside reverse transcriptase inhibitors and a third drug from a different family (non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor). This update presents the causes and criteria for switching ART in patients with undetectable plasma viral load and in cases of virological failure. An update is also provided for the specific criteria for ART in special situations (acute infection, HIV-2 infection, and pregnancy) and with comorbid conditions (tuberculosis or other opportunistic infections, kidney disease, liver disease, and cancer). (C) 2014 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.

Keywords

• Antiretroviral treatment; Human immunodeficiency virus infection; AIDS; Guideline; Recommendations; Antiretroviral drugs; Adverse reactions; GeSIDA; Spanish National AIDS Plan